Objectives: The main objective of this research was to assess the risk of sarcopenia in individuals with PTSD. An additional objective was to evaluate the frequency of testosterone deficiency symptoms in individuals with PTSD and examine the association between the risk of sarcopenia and symptoms of testosterone deficiency. Subjects and Procedures: In this cross-sectional study, 60 veterans who suffer from PTSD and receive treatment at the Psychotrauma Center, Department of Psychiatry, University Hospital of Split, were included. Anamnestic data were collected from all participants, anthropometric measurements and body composition measurements were performed, and blood sample was taken for laboratory analysis. The participants completed the SARC-F questionnaire to assess the risk of sarcopenia and the AMS questionnaire to assess symptoms of testosterone deficiency. Results: In the examined population, 50% of patients with PTSD had an increased risk for sarcopenia. A statistically significant negative correlation was found in the examined population between the risk for sarcopenia and the levels of C-reactive protein (P = 0.049). No statistically significant associations were found between the risk for sarcopenia and the percentage of muscle mass (P = 0.049), percentage of body fat (P = 0.248), and body mass index (P = 0.370). Patients with a higher socioeconomic status (average and above-average) did not have significantly lower risk for sarcopenia compared to patients with below-average socioeconomic status (P = 0.086). Patients without a completed high school education had a significantly higher risk for sarcopenia compared to patients with a high school diploma, higher education, or a professional degree (P = 0.043). Of the total population, only 5% of patients did not have symptoms related to testosterone deficiency, while as many as 73% of patients had severe symptoms associated with testosterone deficiency. Patients with severe symptoms related to testosterone deficiency had a significantly higher risk for sarcopenia compared to patients with milder symptoms or those without symptoms (P = 0.008). The duration of the illness and the time spent in the war were not significantly associated with symptoms of testosterone deficiency assessed by the AMS questionnaire (P = 0.632). Conclusions: Individuals with PTSD, have high prevalence of increased risk for sarcopenia and severe symptoms associated with testosterone deficiency. Patients with lower levels of education and PTSD have a significantly higher risk for sarcopenia. Additionally, patients with 48 PTSD who experience severe symptoms of testosterone deficiency have a significantly higher risk for sarcopenia.